Cosmetic cross-reference Noindex: medium evidence

Visnadine

CAS 477-32-7

Visnadine (CAS 477-32-7) is a Phase 2 pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral / FAERS
Adverse signals
0
SOURCE IUPHAR / PharmGKB
PubMed IDs
0
SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Visnadine
CAS Number
477-32-7
UNII
0RL4V0K263
InChIKey
GVBNSPFBYXGREE-CXWAGAITSA-N
ChEMBL ID
CHEMBL3989444
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2
Mid-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL3989444 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Visnadine used for in pharmaceutical contexts?

Visnadine (CAS 477-32-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Visnadine?

No adverse-event association or SIDER side-effect rows are rendered for Visnadine in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Visnadine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Visnadine with EU status "permitted".

What clinical phase is Visnadine in?

Visnadine is rendered with ChEMBL max phase 2.